Evidence map›Paper›PMID 40170790›Full record

ArticleDrug design, development and therapy2025

Buyang Huanwu Decoction Alleviates Ischemic Stroke Injury by Inhibiting Ferroptosis via the Nrf2/GPX4 Pathway.

Hao Huang, Sijie Liu, Jing Wu, Jiayi Zhu, Jiaxiang Xu, Shuhong Yu, Lingna Bei, Biao Zhang, Yi Luo

Abstract read
In one paragraph

Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hao Huang *Department of Neurology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, People's Republic of China.ORCID 0009-0003-1253-7163
Sijie Liu *Department of Neurology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, People's Republic of China.ORCID 0009-0003-9070-5097
Jing Wu *Department of Traditional Chinese Medicine, Community Health Service Center of the Urban Area, Suzhou, People's Republic of China.
Jiayi ZhuDepartment of Neurology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, People's Republic of China.ORCID 0009-0003-0463-9442
Jiaxiang XuDepartment of Neurology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, People's Republic of China.ORCID 0009-0007-9576-8416
Shuhong YuDepartment of Neurology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, People's Republic of China.
Lingna BeiDepartment of Neurology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, People's Republic of China.
Biao ZhangDepartment of Neurology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, People's Republic of China.
Yi LuoDepartment of Neurology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, People's Republic of China.ORCID 0009-0002-7438-4011

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Acute ischemic stroke poses major challenges due to high disability and mortality rates. Ferroptosis, a form of regulated cell death triggered by iron-induced oxidative stress, plays a key role in stroke injury. Despite its long history in stroke treatment, the mechanism of Buyang Huanwu Decoction (BHD) in ferroptosis remains unclear. Methods: Network pharmacology predicted BHD's active components and pathways, while Ultra Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS) confirmed its main ingredients. Middle Cerebral Artery Occlusion (MCAO) was induced in C57 mice, with neurological deficits and infarct size assessed by Longa scoring and TTC staining. Histopathological and ultrastructural changes were assessed by staining and electron microscopy, and biochemical markers (MDA, GSH, SOD, Fe² Results: Network pharmacology showed BHD targets key pathways in cerebral infarction, including ferroptosis and antioxidant pathways. BHD improved neurological function and reduced the infarct size in MCAO mice by 10% - 50%, and also significantly decreased the levels of oxidative stress markers (MDA, Fe Conclusion: In pre-clinical studies, BHD exerts neuroprotective effects in ischemic stroke by inhibiting ferroptosis through the Nrf2/GPX4 pathway.

Indexed as

Drugs, Chinese HerbalFerroptosisIschemic StrokeNeuroprotective AgentsNF-E2-Related Factor 2Phospholipid Hydroperoxide Glutathione PeroxidaseAnimalsCell SurvivalDisease Models, AnimalDose-Response Relationship, DrugInfarction, Middle Cerebral ArteryMaleMiceMice, Inbred C57BLbuyang huanwuDrugs, Chinese Herbalglutathione peroxidase 4, mouseNeuroprotective AgentsNfe2l2 protein, mouseNF-E2-Related Factor 2Phospholipid Hydroperoxide Glutathione Peroxidasebuyang huanwu decoctionferroptosisischemic strokeNrf2/GPX4 pathway

Identifiers

PMID40170790
PMCPMC11960815

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.